<DOC>
	<DOC>NCT00332046</DOC>
	<brief_summary>Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core symptoms of the disease.</brief_summary>
	<brief_title>fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Inclusion criteria: Primary diagnosis of Social Anxiety Disorder. Willing to restrict alcohol to a limited intake. Exclusion criteria: History of schizophrenia, schizoaffective disorder or a bipolar disorder. Lefthanded. Suffer from claustrophobia. Any reason why subject could not go into the fMRI, for example have metal implants.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>fMRI placebo GW679769 Social Anxiety Disorder SAD</keyword>
</DOC>